Metixene
![]() | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.023.282 |
| Chemical and physical data | |
| Formula | C20H23NS |
| Molar mass | 309.47 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| | |
Metixene (brand names Methixart, CholinFall, Tremonil, Trest), also known as methixene, is an anticholinergic used as an antiparkinsonian agent.[2] It has also been reported to induce incomplete autophagy and cell death in metastatic cancer and brain metastases. [3]
See also
References
- ^ Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.
- ^ Morton IK, Hall JM (1999). "Metixene". Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Dordrecht: Springer Netherlands. p. 178. ISBN 978-94-011-4439-1.
- ^ Fares, Jawad (2023). "Metixene is an incomplete autophagy inducer in preclinical models of metastatic cancer and brain metastases". Journal of Clinical Investigation. doi:10.1172/JCI161142. PMC 10721147. PMID 37847564. Retrieved 3 November 2023.
